Background:Patients with coronary artery disease (CAD) had significantly lower bile acid excretion (BAE) compared with non-CAD patients, leading to the hypothesis that the inability to efficiently excrete bile acids leads to coronary atherosclerosis development. We investigated the long-term role of BAE in CAD development and related mortality in 50 patients with proven CAD compared with that of 50 patients with chest pain and no CAD (controls) matched for clinical and laboratory characteristics.Methods:All subjects received a 4-day standard diet that included ~500 mg of cholesterol. Fecal bile acids from 24-h stool collections were measured by gas liquid chromatography.Results:CAD patients excreted lower amounts of total bile acids than controls (p < 0.001), less deoxycholic acid (p < 0.0001) and less lithocholic acid (p < 0.01). BAE was the best significant independent laboratory factor that predicted CAD (p < 0.05). Mortality and CAD development rates were significantly lower for the controls at the 20-year follow up.Conclusions:These results showed that CAD patients had markedly decreased BAE levels compared with non-CAD controls. BAE <415 mg/day was associated with increased CAD long-term mortality. Impaired ability to excrete cholesterol might be considered an additional independent risk factor for CAD development.
Introduction: How patients cope with a new diagnosis of a serious/life threatening disease has been studied in a variety of settings and diseases, but not in acute myeloid leukemia (AML). In AML patients are confronted with a unique situation of a life-threatening diagnosis and the prospect of intensive prolonged treatments ahead of them. The aim of the current study is to assess different modes of coping with the diagnosis of AML, and whether these strategies remain stable over time. Methods: Adult patients with a new diagnosis of AML who were candidates for intensive chemotherapy and agreed to participate in this study were enrolled. The second author (Dr. Dorfman), a trained psychiatrist, and the chief of the Psycho-Oncology service in our institute, interviewed the patients at diagnosis and 3 months later. In these sessions the patients completed the Mental Adjustment to Cancer (MAC) questionnaire. The Hebrew version of this instrument was previously validated and consists of 40 items that assess the ability to cope with cancer and provides information on four major coping styles: fighting spirit, hopelessness/helplessness, anxious preoccupation and fatalistic acceptance. For each scale we calculated the standard (Z) score. The internal reliability measure (Cronbach's alpha) was above 0.7 for all scales. The sociodemographic interview gathered information on age, education, marital status, living arrangements, country of birth, religion and financial status. Additional medical information was obtained from the electronic medical record of each patient. We compared continuous variables using paired T-test and χ2 to compare categorical variables. We used a multivariate linear regression model to predict which of the baseline characteristics is associated with the coping strategy score. Results: We enrolled 18 patients with a recent diagnosis of AML. The median age was 55 years, and 12 (67%) were males. At time of diagnosis women, single patients (non-married or divorced), and patients with the lowest or highest income levels were significantly more anxious. Those who experienced a major life event within the previous year expressed lowers levels of hopelessness and a lesser degree of a fatalistic mode of coping. On the other hand, male patients, as well as unemployed or patients with low income, tended to express a higher degree of fatalistic feelings. Female patients were less likely to have high levels of fighting spirits. The mode of coping did not remain constant over time, and scores in all 4 scales changed over time. In fact, MAC scores in our cohort at 3 months correlated with baseline scores only in the fatalistic scale ( rp = 0.67, p = 0.006). Conclusion: In patients with newly diagnosed AML facing intensive chemotherapy, socioeconomics factors and life experience dictate, at least in-part, the coping strategy. However, 3 months after starting treatment, these factors become less influential. It is possible that at this stage, other factors, such as response to treatment, residual physical and mental resources and long-term prognosis become more important. Disclosures Wolach: Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaker; AbbVie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaker.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.